BioNTech: From Pandemic Profits to a Fierce Fight Against Cancer
BioNTech is pivoting from its COVID-19 vaccine success to focus on innovative cancer therapies using mRNA technology. Despite a decline in revenue and a net loss of around 700 million…
BioNTech is a biotechnology company based in Mainz, Germany, that focuses on developing and manufacturing active immunotherapies for a patient-specific approach to treating diseases, particularly cancer. Founded in 2008, BioNTech gained global recognition for its role in developing one of the first mRNA-based vaccines for COVID-19, in collaboration with Pfizer. This vaccine utilizes messenger RNA technology to instruct cells in the body to produce a protein that triggers an immune response against the virus. The company is also involved in a range of other vaccine and immunotherapy research and development projects, leveraging its expertise in mRNA technology and personalized medicine. BioNTech’s innovations emphasize the potential of using the body’s immune system to fight various diseases.
BioNTech is pivoting from its COVID-19 vaccine success to focus on innovative cancer therapies using mRNA technology. Despite a decline in revenue and a net loss of around 700 million…